Mushroom configuration can perform corneal cuts

Article

Femtosecond laser (FSL)-assisted mushroom configuration deep anterior lamellar keratoplasty (DALK) is reliable and reproducible, stated a recent noncomparative case series.

Femtosecond laser (FSL)-assisted mushroom configuration deep anterior lamellar keratoplasty (DALK) is reliable and reproducible, stated a recent noncomparative case series.

A research group led by Dr R. Shehadeh-Mashor, Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Canada, performed a noncomparative case series on 19 eyes of 19 patients who had undergone FLS-assisted mushroom configuration DALK. Data was available for assessment at varying times between 1 month to a year postoperatively.

Preoperative BCVA was 20/108 and at 3 and 13 months postoperatively the BCVA was 20/46 and 20/35, respectively. The most significant change in mean spherical equivalent was at 3 months and there was a 56% reduction in mean keratometric cylinder at 6 months.

The complications included three cases of small Descemet membrane perforation, three stromal rejections resolved with topical steroids and six cases of steroid-related IOP rise.

The procedure could mean earlier visual rehabilitation because of the mechanical stability and wound healing advantages of stepped corneal wounds.

The abstract can be found in the latest issue of Cornea.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.